Vaccinex, Inc. (VCNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VCNX POWR Grades
- Sentiment is the dimension where VCNX ranks best; there it ranks ahead of 80.84% of US stocks.
- VCNX's strongest trending metric is Sentiment; it's been moving up over the last 198 days.
- VCNX's current lowest rank is in the Value metric (where it is better than 3.93% of US stocks).
VCNX Stock Summary
- With a price/sales ratio of 107.85, Vaccinex Inc has a higher such ratio than 96.71% of stocks in our set.
- With a year-over-year growth in debt of 711.99%, Vaccinex Inc's debt growth rate surpasses 97.73% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VCNX comes in at -54.53% -- higher than that of just 4.15% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Vaccinex Inc are ADXS, XNET, SLGL, ALT, and SLRX.
- Visit VCNX's SEC page to see the company's official filings. To visit the company's web site, go to www.vaccinex.com.
VCNX Price Target
For more insight on analysts targets of VCNX, see our VCNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
VCNX Stock Price Chart Interactive Chart >
VCNX Price/Volume Stats
| Current price | $2.37 | 52-week high | $9.56 |
| Prev. close | $2.50 | 52-week low | $1.63 |
| Day low | $2.35 | Volume | 271,800 |
| Day high | $2.54 | Avg. volume | 4,195,415 |
| 50-day MA | $2.98 | Dividend yield | N/A |
| 200-day MA | $3.23 | Market Cap | 67.41M |
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Latest VCNX News From Around the Web
Below are the latest news stories about Vaccinex Inc that investors may wish to consider to help them evaluate VCNX as an investment opportunity.
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTechZacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech |
Bet on Rising P/E With These 5 Top-Ranked StocksWant to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios. |
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access EventROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Maurice Zauderer, Ph.D., President and CEO, will host 1x1 meetings and will present a corporate update on Wednesday, January 6th at 11am EST.To register to listen to the presentation or to request a meeting, visit: http://lifesci.events/LifeSci2021About Vaccinex, Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver ... |
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical ConferenceSIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’sROCHESTER, N.Y., Oct. 29, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Vaccinex, Inc. (Nasdaq: VCNX) please note that the original version of this press release, the third paragraph indicated that interested participants would be able to register for HSG at no charge, however there is a nominal fee and interested participants may register for the event here. The corrected release follows:Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pione... |
Vaccinex, Inc. to Present at the Virtual Investor KOL RoundtableLive moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDTROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced today that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 10:00 AM ET. Participating in the KOL Roundtable discussion will be Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex and Eric Siemers, MD, President, Siemers Integrations LLC and Former Distinguished Medical Fellow for Eli Lilly and Company's Al... |
VCNX Price Returns
| 1-mo | -18.28% |
| 3-mo | -23.05% |
| 6-mo | 35.43% |
| 1-year | -35.07% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 14.49% |
| 2020 | -57.32% |
| 2019 | 33.06% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching VCNX
Want to do more research on Vaccinex Inc's stock and its price? Try the links below:Vaccinex Inc (VCNX) Stock Price | Nasdaq
Vaccinex Inc (VCNX) Stock Quote, History and News - Yahoo Finance
Vaccinex Inc (VCNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...